Trillium Group

Omni-ID Ltd. specializes in developing passive ultra high frequency radio frequency identification (RFID) technology products that are designed for efficient asset tracking and management. The company offers a range of RFID tags, including the Max and Flex tags for various applications such as conveyance, industrial devices, and retail shelving. Additionally, Omni-ID provides the Prox tag for IT asset identification and the ProVIEW system, which combines visual instructions with RFID tracking and process communication software. Their products are engineered to perform reliably in challenging environments, including those involving metals and liquids, ensuring accurate identification of high-value assets. Founded in 2007 and based in Farnham, United Kingdom, Omni-ID serves diverse sectors including information technology, telecommunications, industrial, and retail markets, focusing on cost-effective solutions for tagging, tracking, and monitoring applications.

Omni-ID Ltd. specializes in developing passive ultra high frequency radio frequency identification (RFID) technology products that are designed for efficient asset tracking and management. The company offers a range of RFID tags, including the Max and Flex tags for various applications such as conveyance, industrial devices, and retail shelving. Additionally, Omni-ID provides the Prox tag for IT asset identification and the ProVIEW system, which combines visual instructions with RFID tracking and process communication software. Their products are engineered to perform reliably in challenging environments, including those involving metals and liquids, ensuring accurate identification of high-value assets. Founded in 2007 and based in Farnham, United Kingdom, Omni-ID serves diverse sectors including information technology, telecommunications, industrial, and retail markets, focusing on cost-effective solutions for tagging, tracking, and monitoring applications.

OyaGen, Inc. is a biotechnology company based in Rochester, New York, established in 2003. The company specializes in the discovery, development, and commercialization of pharmaceutical therapies that leverage RNA and DNA editing enzymes. Its innovative platform technology focuses on editing enzymes that can influence a variety of biological functions, including antiviral responses, cancer treatment, immunoglobulin gene rearrangements, inflammation, ion channel activity, LDL reduction, neuro-cognitive functions, and the expression of red blood cells in the fetal liver. By chemically altering RNA or DNA molecules, OyaGen aims to provide enhanced therapeutic options for conditions such as human immunodeficiency virus and other diseases.

ClearMomentum, Inc. offers financial reporting software tailored for venture capital and private equity investors, boards, and limited partners. Founded in 2005 and headquartered in Canandaigua, New York, the company developed the first private equity portfolio management solution designed to streamline the collection, analysis, reporting, and distribution of portfolio company data. Its flagship product, ClearFinancials, serves as a portfolio monitoring application that validates and synthesizes private company financial statements while facilitating collaboration through a web portal for sharing investment documents and creating custom workflows. Additionally, ClearMomentum provides an iPad application that allows users to monitor financial metrics, access historical data, and personalize their dashboards. The company addresses critical issues in data management and reporting by offering a structured data warehouse to archive disparate documents securely. ClearMomentum’s solutions aim to enhance data transparency, accuracy, and timeliness for alternative asset investors, thereby improving efficiency in portfolio company financial reporting.

iCardiac Technologies, Inc. specializes in cardiac safety biomarkers, focusing on the assessment of drug safety profiles through its Dynamic QTbtbsm suite of ECG-based markers. Founded in 2006 and headquartered in Rochester, New York, the company offers a comprehensive range of services that include scientific and medical consultation, study design, data management, ECG analysis, statistical reporting, and regulatory interface. iCardiac's advanced methodologies aim to enhance the precision and accuracy of cardiac safety evaluations in clinical trials, supporting pharmaceutical, biotechnology, and medical device companies in their drug development processes. By providing these specialized services, iCardiac helps ensure that subjects are appropriately included in studies, thereby facilitating more efficient drug development programs.

Communication Synergy Technologies Inc., a Rochester, N.Y.–based developer of document management solutions.

Appairent Technologies, Inc. is a wireless multimedia systems and solutions company that provides radio modules, software and intellectual property to major consumer-electronics manufacturers. Their products - based on industry standards - employ cutting-edge technology to deliver low-power and low-cost streaming multimedia applications, from digital cameras and personal data assistants, to televisions, set-top boxes, MP3 players, laptop computers, digital camcorders and more. Appairent Technologies was formed - and is operated - by experienced consumer-electronics experts, including leaders of the IEEE 802.15 working group and an original co-founder of the 802.11 working group. They're proud to be a member of the IEEE-standards activities and a founding member of the WiMedia Alliance. Appairent Technologies spun off as an independent company from Eastman Kodak Company in January 2002.

VirtualScopics, Inc. specializes in providing imaging services tailored for the pharmaceutical, biotechnology, and medical device sectors, particularly during clinical trials. The company develops a range of image analysis software tools and applications that facilitate the detection and measurement of specific anatomical structures and metabolic activity through medical imaging. Its proprietary technology enables accurate and reproducible assessments of subtle changes in anatomical structures associated with diseases such as oncology, cardiology, neurology, and musculoskeletal disorders. Additionally, VirtualScopics has established strategic partnerships to enhance its offerings, including collaborations with PPD Development, IXICO, and Micron to provide integrated solutions for clinical development and imaging needs across various therapeutic areas. Founded in 1988 and headquartered in Rochester, New York, the company operates as a subsidiary of BioTelemetry, Inc. since 2016.